Back to Agenda
Expedited E2B Safety Reporting in Interventional Clinical Trials: Convergence of Global Expectations?
Session Chair(s)
William Gregory, PhD
Senior Director, Safety and Risk Management
Pfizer Inc, United States
FDA has provided guidance to sponsors on systematic approaches to IND safety reporting that focus on informative reports of important safety information. To enhance the efficiency of this process, FDA has initiated a pilot program for the submission of IND safety reports in a standardized, structured format that follows the ICH E2B standard (with certain regional modifications). Likewise, for expedited clinical trial safety reports in Japan and elsewhere. This forum is designed to provide a balanced discussion of clinical trial electronic case reporting requirements based on audience interest. The forum will include lessons learned from the ongoing US pilot and a comparison with the clinical trials reporting situation in Japan. Each of the expert panel members will provide brief introductory comments and, at the conclusion of prepared remarks, the panel will entertain Q&A.
Learning Objective : Discuss the importance of providing informative IND safety reports to FDA and high-level requirements for submission of ICSRs in E2B format; Describe the benefits and challenges of implementing structured electronic safety reports from clinical trials in the US and Japan; Outline initiatives in the US and Japan to improve and streamline expedited clinical trial safety reporting.
Speaker(s)
Safety Reporting Practices: Current State, Efforts to Streamline the Process, and the Case for a Global Safety Database
Tamy Kim, PharmD
FDA, United States
Director, Regulatory Affairs/ Regulatory Policy, Oncology Center of Excellence
Emerging New PV World: Comparison of and Exploring New Guidelines for Clinical Research in Japan
Teiki Iwaoka, PhD, MS
Rockhill Consulting, Japan
Director, Pharmacovigilance, Clinical Development
Directional Roadmap for ICSR Data Standards and Harmonized Case Reporting
Ta-Jen Chen, MS
FDA, United States
Project Management Officer, OSP, CDER
FAERS II
Suranjan De, MBA, MS
FDA, United States
Deputy Director, Regulatory Science, OSE, CDER
Industry Perspective
Dieter Kempf, MS
Genentech, A Member of the Roche Group, United States
Group Director, PV Intelligent Automation and Business Systems Solutions
Have an account?